Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.32 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.31 |
| ▸ | ITGAV | P06756 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438372 | 1.00 | NPC1 (0.37) | NPC1RAB9AMMEITGB1ITGA5 | |
| SCHEMBL1493211 | 0.86 | NPC1 (0.38) | NPC1RAB9AMMEITGB1ITGA5 | |
| SCHEMBL438992 | 0.85 | MEN1 (0.43) | NPC1RAB9ACA2MAOB | |
| SCHEMBL438991 | 0.85 | MEN1 (0.43) | NPC1RAB9ACA2MAOB | |
| SCHEMBL443089 | 0.84 | KMT2A (0.38) | NPC1RAB9AITGB1CA2 | |
| SCHEMBL437798 | 0.84 | KMT2A (0.38) | NPC1RAB9AITGB1CA2 | |
| SCHEMBL437797 | 0.84 | KMT2A (0.38) | NPC1RAB9AITGB1CA2 | |
| SCHEMBL13814005 | 0.83 | NPC1 (0.36) | NPC1RAB9AITGB1ITGA5SOAT1 | |
| SCHEMBL1493215 | 0.83 | NPC1 (0.36) | NPC1RAB9AITGB1ITGA5SOAT1 | |
| SCHEMBL13814007 | 0.83 | NPC1 (0.36) | NPC1RAB9AITGB1ITGA5SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20040208828-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040208828-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents | CYP4B1, CYP2B6, UGT2B7 | NPC1 875/4885RAB9A 676/4885MME 1747/4885 |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | CYP4B1, CYP2B6, UGT2B7 | NPC1 881/4885RAB9A 675/4885MME 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.